drugset / Trial / NCT03193684
Empagliflozin and Hepatic Glucose Metabolism
Phase 4
Completed
72 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake
Timeline
- Start
- 2018-05-20
- Primary completion
- 2023-01-30
- Completion
- 2024-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | — |
Indications
No indication recorded.